Format

Send to

Choose Destination
Drug Discov Today. 2017 Jul;22(7):1056-1063. doi: 10.1016/j.drudis.2017.01.017. Epub 2017 Feb 7.

Emerging RNA editing biomarkers will foster drug development.

Author information

1
Sys2Diag FRE3690 CNRS/ALCEDIAG, Complex System Modeling and Engineering for Diagnosis, Cap delta/Parc Euromédecine, 1682 rue de la Valsière CS 61003, 34184 Montpellier Cedex 4, France. Electronic address: siem.van-der-laan@sys2diag.cnrs.fr.
2
Sys2Diag FRE3690 CNRS/ALCEDIAG, Complex System Modeling and Engineering for Diagnosis, Cap delta/Parc Euromédecine, 1682 rue de la Valsière CS 61003, 34184 Montpellier Cedex 4, France.
3
Sys2Diag FRE3690 CNRS/ALCEDIAG, Complex System Modeling and Engineering for Diagnosis, Cap delta/Parc Euromédecine, 1682 rue de la Valsière CS 61003, 34184 Montpellier Cedex 4, France. Electronic address: franck.molina@sys2diag.cnrs.fr.

Abstract

Unanticipated adverse drug reactions (ADRs) on the central nervous system are a major cause of clinical attrition and market withdrawal. Current practices for their prospective assessment still lean on extensive analysis of rodent behaviour despite their highly controversial predictive value. Human-derived in vitro models that objectively quantify mechanism-related biomarkers can greatly contribute to better ADR prediction at early developmental stages. Adenosine-to-inosine RNA editing constitutes a physiological cellular process that translates environmental cues by regulating protein function at the synaptic level in health and disease. Robust solutions based on NGS-based quantification of RNA editing biomarkers have emerged to predict the likelihood of treatment-related suicidal ideation and behaviour allowing cost-effective high-throughput drug screening as a strategy for risk mitigation.

PMID:
28188894
DOI:
10.1016/j.drudis.2017.01.017
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center